Clinical Trial Update: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the combination of durvalumab and tremelimumab as first-line therapy for advanced hepatocellular carcinoma has results posted; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-18